Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018224

Enrollment

Unknown

Registered

2018-09-05

Start date

2018-09-10

Completion date

Unknown

Last updated

2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis

Interventions

Preventive treatment group:Combination of isoniazid and rifapentine for six weeks, twice for one week with a maximum dosage of 600 mg

Untreated group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Residents living in local areas for 6 months or more; 2) aged younger than 75 years old; 3) with a history of tuberculosis treatment before June 2016 or with chest radiography evidence for prior tuberculosis, and no drug resistance record for RPT/INH; 4) positivity IGRA; 5) informed consent by voluntarily signed.

Exclusion criteria

Exclusion criteria: 1) with a history of tuberculosis identified after June 2016; 2) with a history of relapse for tuberculosis; 3) pregnant or lactation; 4) extrapulmonary tuberculosis,central nervous system diseases, tumors, AIDS, HCV infection; 5) history of drug allergy or dysfunction of liver and kidney; 6) subjects who have no full capacity or are unable to promite to complete the entire study period.

Design outcomes

Primary

Measure	Time frame
Diagnosis of active pulmonary tuberculosis;	—

Countries

China

Contacts

Public ContactLei Gao

Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College

geolei@ipbcams.ac.cn+86 10 6782 8550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026